clinical trial · NCT05007392
A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
Eisai Co., Ltd.·phase3·completed·n = 451
GoutDotinuradFebuxostatDotinurad Matched PlaceboFebuxostat Matched Placebo
brief summary
The primary purpose of the study is to confirm the efficacy of dotinurad 4 milligram (mg) to febuxostat 40 mg on the percentage of participants achieving a serum uric acid (SUA) level less than or equal to (\<=) 6.0 milligrams per deciliter (mg/dL) at Week 24 in Chinese participants with gout.
started
Dec 21, 2021
primary completion
Jun 14, 2023
completion
Jun 14, 2023
last updated
Jul 30, 2025
official title
A Randomized, Multicenter, Double-Blind, Superiority Study of Dotinurad (4 mg) and Febuxostat (40 mg) for the Treatment of Subjects With Gout
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol